Douglas Kerr Biography and Net Worth

Insider of Dyne Therapeutics

Dr. Kerr brings more than 25 years of expertise in early-and late-stage clinical development, with deep experience in neurology. For the last year, he was a venture partner at Atlas Venture. From 2017 to 2023, he was an integral member of Generation Bio, joining initially as the head of research and development and most recently serving as its CMO. Previously, he oversaw neurology-focused franchises at Shire, and prior to that he held senior positions at Biogen where he was the global lead for a series of programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Dr. Kerr holds a B.A. in biochemistry from Princeton University and an M.D. from Jefferson Medical College, as well as his Ph.D. in molecular biology from Thomas Jefferson University. He obtained his MBA, with a specialization in entrepreneurship and finance from Northeastern University and completed his medical residency at Johns Hopkins School of Medicine and served on their faculty for 10 years.

What is Douglas Kerr's net worth?: The estimated net worth of Douglas Kerr is at least $2.93 million as of May 13th, 2026. Kerr owns 170,042 shares of Dyne Therapeutics stock worth more than $2,934,075 as of June 2nd. This net worth approximation does not reflect any other assets that Kerr may own. Learn More about Douglas Kerr's net worth.
How do I contact Douglas Kerr?: The corporate mailing address for Kerr and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at [email protected]. Learn More on Douglas Kerr's contact information.
Has Douglas Kerr been buying or selling shares of Dyne Therapeutics?: Over the course of the past ninety days, Douglas Kerr has sold $28,715.04 of Dyne Therapeutics stock. Most recently, Douglas Kerr sold 1,564 shares of the business's stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a transaction totalling $28,715.04. Following the completion of the sale, the insider now directly owns 170,042 shares of the company's stock, valued at $3,121,971.12. Learn More on Douglas Kerr's trading history.
Who are Dyne Therapeutics' active insiders?: Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Johanna Friedl-Naderer (Chief Commercial Officer), Susanna High (COO), Carlo Incerti (Director), Douglas Kerr (Insider), Dirk Kersten (Director), Erick Lucera (CFO), Brian Posner (Director), Jason Rhodes (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.
Are insiders buying or selling shares of Dyne Therapeutics?: During the last year, Dyne Therapeutics insiders bought shares 4 times. They purchased a total of 107,500 shares worth more than $1,035,400.00. During the last year, insiders at the sold shares 15 times. They sold a total of 1,562,102 shares worth more than $29,850,148.21. The most recent insider tranaction occured on May, 26th when Director Brian S Posner bought 2,000 shares worth more than $36,420.00. Insiders at Dyne Therapeutics own 9.5% of the company. Learn More about insider trades at Dyne Therapeutics.
Information on this page was last updated on 5/26/2026.

Douglas Kerr Insider Trading History at Dyne Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/13/2026	Sell	1,564	$18.36	$28,715.04	170,042

Douglas Kerr Buying and Selling Activity at Dyne Therapeutics

Dyne Therapeutics Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $17.12

$18.17

$19.19

50 Day Range

MA: $18.31

$15.92

$20.41

2 Week Range

Now: $17.12

$8.06

$25.00

Volume

1,442,215 shs

Average Volume

1,338,612 shs

Market Capitalization

$2.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09